2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2628

Raynaud’s Symptoms and Pregnancy Induced Hypertension in Patients with Systemic Lupus Erythematosus
Abstract Number: 2213

“Generalized Osteoarthritis”: Update to a Systematic Review
Abstract Number: 2008

“Intrathoracic Manifestations of Connective Tissue Diseases on High Resolution Computed Tomography”
Abstract Number: 1588

“Neoplasia in Patients with Systemic LUPUS Erythematosus in Spain: Relesser Registry DATA”
Abstract Number: 1614

“Do You Know What I Mean?” a Tool to Understand What Lupus Patients Comprehend
Abstract Number: 1753

“Recurrent Venous Thromboembolic Events in Granulomatosis with Polyangiitis Patients”
Abstract Number: 848

“Suddenly You Are a Person at Risk of Developing Rheumatoid Arthritis!” Different Perspectives of Individuals on Predictive Testing – Results of an International Qualitative Interview Study
Abstract Number: 1275

101 Juvenile Myositis Patients Characterized By Myositis Specific Antibodies: Disease Activity and Damage over 60 Months
Abstract Number: 2327

14-3-3η (eta) Protein in Juvenile Idiopathic Arthritis (JIA) Patients
Abstract Number: 1355

14-3-3η: Useful for More Than the Diagnosis of Rheumatoid Arthritis?
Abstract Number: 1643

15 Year Comparative Analysis of Cardiovascular Events in Female Subjects with Lupus Versus Controls
Abstract Number: 2003

18 FDG PET/CT Predicts Decline in Functional Respiratory TESTS in Systemic Sclerosis Patients but NOT in Rheumatoid Arthritis Patients
Abstract Number: 2658

4-Hydroxy-2-Nonenal Serum Protein-Adducts and Anti-4-Hydroxy-2-Nonenal-Protein Adduct Antibodies in SLE
Abstract Number: 885

48-Week Complete Remission By Ethnic, Sex and Age Subgroups in Patients with Active Lupus Nephritis Treated with Voclosporin
Abstract Number: 2835

5-Year Evolution Patterns of Physical Activity and Sedentary Behavior of Patients with Symptomatic Hip and/or Knee Osteoarthritis, and Their Sociodemographic and Clinical Correlates

1
2
3
…
201
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].